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Abstract
While anti-cancer therapies, including chemotherapy, immunotherapy, radiotherapy, and targeted therapy, are constantly ad-
vancing, cardiovascular toxicity has become a major challenge for cardiologists and oncologists. This has led to an increasing
demand of cardio-oncology units in Europe and a growing interest of clinicians and researchers. The Heart Failure 2019 meet-
ing of the Heart Failure Association of the European Society of Cardiology in Athens has therefore created a scientific pro-
gramme that included four dedicated sessions on the topic along with several additional lectures. The major points that
were discussed at the congress included the implementation and delivery of a cardio-oncology service, the
collaboration among cardio-oncology experts, and the risk stratification, prevention, and early recognition of cardiotoxicity.
Furthermore, sessions addressed the numerous different anti-cancer therapies associated with cardiotoxic effects and
provided guidance on how to treat cancer patients who develop cardiovascular disease before, during, and after treatment.
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Introduction
More than 32 million people worldwide suffer from cancer.1
In the last years, advances in anti-cancer therapies have led
to an improvement in life expectancy of different cancer
types.2 These patients often suffer from multiple different
co-morbidities that may develop as consequences from
anti-cancer therapies. Frequent problems include, but are
not limited to, chronic kidney disease,3,4 liver dysfunction,5,6
gastrointestinal disease,7,8 anaemia,9,10 fatigue,11,12 infec-
tions,13,14 anorexia15,16, muscle wasting,17,18 pain,19,20 and
heart failure (HF).21,22 Depending on the cancer diagnosis
and the type of anti-cancer treatment, cardiotoxicity rates
may vary from 0% to 48% of patients, with HF being a
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predominant presentation.23 HF is associated with a 5-year
survival rate of nearly 50%24–26 and is frequently accompa-
nied by reduced quality of life.27 HF is characterized by mul-
tiple symptoms such as reduced physical performance,28
shortness of breath,29 fluid retention,30 general weakness
31, and prolonged hospital stays32, which ultimately also re-
sult into substantial healthcare costs.33
Besides HF, other frequent cardiovascular (CV) problems
associated with anti-cancer therapies include coronary artery
disease,34 atrial fibrillation,35 arterial hypertension,36 throm-
boembolic disease37, valvular disease38, pulmonary hyperten-
sion,39 stroke,40 and peripheral vascular disease.41 Special
populations at increased short-term and long-term risks for
CV disease are paediatric.42 and elderly patients43 Depending
on the cancer entity, up to 30% of cancer patients eventually
die of CV disease.44
The ‘Heart Failure and World Congress on Acute Heart Fail-
ure 2019’ provided a great platform for experts in cardio-
oncology to meet and exchange the latest ideas and advances
in cardio-oncology. The congress was held in Athens, Greece,
from 25 May 2019 to 28 May 2019, and was attended by
5431 delegates, including more than 285 faculty members
in more than 120 scientific sessions. During the congress, four
full-dedicated sessions, additional lectures, various clinical
cases, and posters were dedicated to cardio-oncology. Ex-
perts in the field discussed how to identify, treat, and prevent
CV problems in cancer patients and were involved in interac-
tive discussions with the audience. A detailed list of all ses-
sions can be found in Supporting Information, Table S1.
Cardiovascular disease in cancer
Cardiovascular events in cancer patients can be caused by
three main factors: (i) concomitant CV risk factors and
diseases; (ii) anti-cancer therapy (including chemotherapy,
targeted therapy, immune checkpoint inhibitors, and radia-
tion) through direct or indirect damage effects; (iii) cancer it-
self, through the direct invasion of CV structures or indirect
release of metabolites and/or activation of adrenergic sys-
tem45–47 (Figure 1).
Dr Peter van der Meer (Groningen, the Netherlands), Dr
Christian Bär (Hannover, Germany), and Associate Professor
Dimitrios T. Farmakis (Athens, Greece) presented cancer
therapy-related cardiomyopathy (CTRCM).24,48 A recent 10-
year follow-up study with 350 breast cancer survivors previ-
ously treated with chemotherapy and/or radiation therapy
compared with 350 age-matched healthy women demon-
strated an increased risk of mild left ventricular (LV) dysfunc-
tion in cancer survivors (15.3% vs. 7%).49 These data
underline a long-term risk for cardiac dysfunction in cancer
patients previously treated with specific chemotherapy
and/or radiotherapy.23 The intersection between HF and can-
cer was explored by Associate Professor Farmakis and Profes-
sor Denise Hilfiker-Kleiner (Hannover, Germany). Both
entities share several risk factors (ageing, tobacco, adiposity,
physical inactivity, and infections) and an underlying systemic
inflammatory status.50–52 In the CANTOS trial,53 which in-
cluded 10 061 patients with myocardial infarction and in-
creased high-sensitive C-reactive protein, the inhibition of
the cytokine interleukin 1β with canakinumab (patients ran-
domized to 50, 150, and 300mg, or placebo) showed a reduc-
tion of nonfatal myocardial infarction, nonfatal stroke, or CV
death with 150 mg canakinumab.54 A secondary analysis of
the data by Ridker et al.55 showed a reduction of lung cancer
incidence (with 150 and 300 mg canakinumab vs. placebo)
and lung cancer mortality (with 300 mg of canakinumab vs.
placebo). Further studies are needed to validate these re-
sults. Dr Markus Anker (Berlin, Germany) discussed CV prob-
lems of cancer patients beyond anti-cancer therapy
Figure 1 Aetiology of cardiovascular disease in cancer patients.
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associated cardiotoxicity. It has previously been shown that
treatment-naïve colorectal cancer patients also demon-
strated a mildly reduced left ventricular ejection fraction
(LVEF) compared with healthy controls of similar age and
sex56. The resting heart rate of cancer patients has also been
found to be an independent predictor of all-cause mortality in
patients with pancreatic, colorectal, and non-small cell lung
cancer57. This was confirmed in a large retrospective cohort
of 4786 patients with breast cancer58. A recent analysis in
305 advanced colorectal adenoma patients suggested higher
adenoma recurrence rates in those patients with higher heart
rates59. These effects might be related to a sympathetic acti-
vation in some patients, like it has been shown for HF60. More
studies are needed to better understand the underlying
mechanisms.
Diagnosis and prevention
Dr Teresa Lopez-Fernandez (Madrid, Spain) addressed differ-
ent cardiac imaging methods in cancer patients. Imaging is
useful to stratify the risk profile at baseline, to predict recov-
ery from cardiac injuries during cancer treatment and to de-
tect early as well as late-onset of cardiac dysfunction in
cancer survivors61 (Figure 2). Dr Lopez-Fernandez accentu-
ated the fundamental role of transthoracic echocardiography
in modern day cardio-oncology, because it is ubiquitously
available, involves no radiation exposure, and can also assess
haemodynamics.23 Cardiotoxicity, according to the 2016 ESC
Position Paper on cancer treatments and CV toxicity,23 is
defined as a decrease of LVEF by >10 percentage points, be-
low the local lower limit of normality (50–55%). According to
recent opinions, 3D echocardiography may be preferable
over 2D echocardiography (2DE) to assess LVEF in cancer pa-
tients, because of its low analysis time, higher reproducibility,
and higher feasibility.62,63 3D echocardiography has demon-
strated to outperform 2DE in detecting LVEF changes in can-
cer patients.64 Global longitudinal strain has arisen as another
parameter to characterize myocardial tissue in the past years.
It permits the early identification of myocardial deformation
abnormalities, with high reproducibility, before the detection
of left ventricular systolic dysfunction (LVSD) by 2DE.65
But much more research is needed into global longitudinal
strain and its implications for the treatment of cancer pa-
tients.66 In addition, Dr Lopez-Fernandez showed new data
on right ventricle strain as a novel and sensitive predictor of
cardiotoxicity.67 Cardiac magnetic resonance is very accurate,
has an excellent reproducibility, and allows tissue characteri-
zation of the heart.23,68 However, Dr Lopez-Fernandez ex-
plained that cardiac magnetic resonance is not used in daily
practice due to its high costs and limited availability only in
larger clinical centres.
Blood biomarkers as predictors of subclinical cardiotoxic in-
jury were discussed by Dr Daniela Cardinale (Milan, Italy). Ab-
normal levels of troponins are considered a sensitive marker
for cardiac monitoring to detect early cardiac-specific injury
and asymptomatic LVSD in cancer patients during potentially
cardiotoxic anti-cancer therapy,69 and they are also used to
stratify the risk of cardiotoxicity before cancer therapy.70 Per-
sistently increased N-terminal pro B-type natriuretic peptide
during high-dose chemotherapy have also shown to predict
long-term LVEF reduction in cancer patients.71 Combined
measurements of N-terminal pro B-type natriuretic peptide
as markers of CV overload and troponins for myocardial in-
jury during cancer therapy may be useful.72 Lastly, microRNA
were discussed as potential new biomarkers in cardio-
oncology.73
Professor Radek Pudil (Hradec Kralove, Czech Republic)
and Dr Kalliopi Keramida, (Athens, Greece) talked about dif-
ferent prevention strategies in order to minimize the devel-
opment of CTRCM. The proposed approach consists of
three different intervention phases according to the imple-
mentation of anti-cancer treatment. The aim of the first
phase is to stratify the patients into low-risk, medium-risk,
and high-risk groups for cardiotoxicity during anti-cancer
treatment.74 The identification of high-risk patients is impor-
tant in order to apply adequate measures, including optimiza-
tion of CV risk factors and pre-existing CV disease, planning of
active screening during therapy and interdisciplinary cardio-
oncologic decisions for the anti-cancer treatment with the
best benefit/risk ratio.75 Additionally, beneficial effects of ex-
ercise training before and during cancer therapy have been
demonstrated.76–78 The second phase concentrates on identi-
fying patients with LVSD during treatment. Frequently used
Figure 2 Diagnostic methods for early detection of cardiotoxicity.
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and inexpensive screening tools include serial troponin mea-
surements and regular echocardiographic monitoring of
LVEF.23,79 Both speakers agreed that in case of cardiac dys-
function, a decision for continuation of treatment of the pa-
tient can only be made by the close collaboration between
cardiologists and oncologists.23 The third phase of prevention
consists of long-term surveillance of cancer survivors. Associ-
ate Professor Farmakis quoted a study by Mertens et al.80 in
20 227 childhood cancer survivors that found cardiac mortal-
ity to be 8.2 times higher compared with the general popula-
tion with no previous cancer diagnosis. CV disease can
develop many years after diagnosis and treatment of can-
cer.81 Associate Professor Farmakis recommended cardiolo-
gists to follow-up high-risk cancer patients after completion
of anti-cancer treatment. Surveillance tools may include elec-
trocardiograms, echocardiography, cardiac biomarkers, ca-
rotid ultrasound, fasting lipid profile, TSH in case of neck
irradiation, and regular measurement of blood pressure.23,82
Cardio-oncology services have become very important and
continue to grow in oncological clinical care. Dr Alexander
Lyon (London, UK) and Dr Lopez-Fernandez discussed during
their presentations how to establish such a service. Cardio-
oncology services can help optimizing anti-cancer treatment,
avoiding delays, and allowing adequate treatment of CV com-
plications.83 They also play a key role in the prevention of
cardiotoxicity. Cardio-oncology units are composed of pri-
mary care departments, outpatient clinics, and educational
programmes.84 Recent data from Pareek et al.84 demon-
strated the effectiveness of these services. From 128 cancer
patients with LVSD, 88% of patients were able to continue
their cancer therapy after CV optimization, while an improve-
ment of LVSD after 1 year of follow-up was shown in 94% of
patients. Professor Thomas Thum (Hannover, Germany) rec-
ommended the promotion of basic, translational, and clinical
research, training programmes, as well as educational re-
sources as the foundation to a successful cardio-oncology
workforce for the care of cancer patients. Lastly, the speakers
also talked about the need to actively involve the patients in
all decisions, so that patients can make informed decisions to-
gether with the treating physicians about possible treatment
strategies.
Treatment of cardiotoxicity and new
frontiers
Professor Alain Cohel-Solal (Paris, France) and Professor Rud-
olf de Boer (Groningen, the Netherlands) talked about avail-
able CV therapies to manage CTRCM. Because of its peculiar
phenotype (tachycardia, low blood pressure, LV and/or right
ventricular involvement, and dilated ventricles), intervention
strategies may be challenging.85 One of the largest studies re-
garding this question was conducted by Cardinale et al.82 The
authors followed 2625 cancer patients for a median of 5
years. During the first year of follow-up, echocardiography
was conducted every 3 months, then for another 4 years ev-
ery 6 months, and after that once a year. Cardiotoxicity was
defined as a drop of LVEF below 50% and by >10 percentage
points, which is similar to the current definition of
cardiotoxicity by the ESC.23 When cardiotoxicity occurred,
HF therapy with angiotensin-conversion enzyme inhibitors
(ACE-Is) and beta-blockers was initiated and up-titrated to
the maximum tolerated dose. In the entire study,
cardiotoxicity occurred in 221 patients (9%); 98% of all
cardiotoxic events occurred within the first year of follow-
up. This underlines the importance of closely monitoring can-
cer patients during the first year after a potentially
cardiotoxic therapy. Of those patients with cardiotoxicity
who initiated HF therapy with ACE-Is and beta-blockers,
82% had at least a partial recovery of LVEF. In patients, in
whom ACE-I or BB therapy cannot be up-titrated due to ad-
verse effects like hypotension, Professor Cohen-Solal consid-
ered ivabradine as a possible additional treatment for
selected patients86 and the need to be more cautious in drug
titration in these patients than in other patients with cardiac
dysfunction. There is also a need to investigate the effects
and possible benefits of sacubitril/valsartan for the treatment
of CTRCM.87
During the congress, the preliminary results of MADIT-CHIC
Study (NCT02164721) by Singh et al.88,89 were also discussed.
Thirty patients (87% female) with CTRCM and lymphoma or
breast cancer, which qualified for cardiac resynchronization–
defibrillator therapy, participated in the trial. The primary end-
point, change of LVEF at 6 months, increased by 11% (95% CI
8–14; P< 0.001) and was independent of age, sex, NYHA class,
and QRS duration. LV end-diastolic volume, LV end-systolic
volume, and left atrial volume decreased. Weaknesses of the
trial were the short period of follow-up, the primarily female
patient population, the lack of control group, and only 30 in-
cluded patients while the trial ran for 3.5 years. Larger ran-
domized trials will have to further investigate the potential
benefits of cardiac resynchronization–defibrillator therapy in
CTRCM.
Dr Javid Moslehi (Nashville, TN, USA) focused on immune
checkpoints inhibitors (ICIs). Immunotherapy (e.g. anti-CTLA-
4, anti-PDL-1, and anti-PD-1) can be used as monotherapy or
in combination with other chemotherapies, for example, in ad-
vanced melanoma90 and advanced, refractory non-small-cell
lung cancer.91 Adverse events like myositis, mucositis, colitis,
and pneumonitis can accompany the administration of these
anti-cancer agents.92 ICI-associated myocarditis is infrequently
seen after the administration of 1-2 drug doses but associated
with high rates of mortality of early 50%93. According to Dr
Moslehi, a deeper understanding of the underlying pathophys-
iological mechanisms is urgently needed.94,95 Therefore, spe-
cific knockout models in mice have been developed to
further study ICI-related mechanisms and underlying
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pathways96. Professor Carlo Gabriele Tocchetti (Naples, Italy)
further deepened the concept about the importance of immu-
nology in cardio-oncology:97 not only can immunologic path-
ways be exploited to fight cancer98 and predict the response
to anti-cancer therapies99 but also they are involved in the de-
velopment of cardiotoxicity.100
Professor Dirk Brutsaert (Antwerp, Belgium) discussed how
an impairment of the endothelium could influence the prog-
ress of HF and cancer. According to him, the endothelium
has haemodynamic, mechanical, and biochemical sensors
for several molecules like proteins, microvesicles, peptides,
and microRNA.101 As an organ with perfusion and transport
function, endothelial cells secrete growth inhibitors and per-
mit the extravasation of cells.102 Professor Brutsaert there-
fore hypothesized that endothelial dysfunction might play
an important role in the development of both cancer and
HF.103
Conclusions
The ‘Heart Failure and World Congress on Acute Heart Failure
2019’ gave the participants a great overview of the current
knowledge in cardio-oncology and new directions of this re-
search area. Some of the cornerstones of cardio-oncology in-
clude the assessment of CV risk profiles in cancer patients
before the initiation of anti-cancer treatment, the effective
and adequate monitoring techniques for cardiotoxicity, the
design of patient specific management strategies, and the
need to universally introduce cardio-oncology services in hos-
pitals working in close collaboration with oncology
departments.
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